c A delay of up to 60 days between treatment cycles will be allowed. 1Tumor biopsies will be assessed by immunohistochemistry (IHC) 2If optional biopsy performed 3Optional biopsy 4FNA (Fine Needle Aspirate): before the excisional/incisional/core biopsy 5Gene Expression Analyses of tumor biopsies, FNA, and PBMC 6Serum chemistries include: albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glu cose, phosphorus, potassium, total protein, SGOT [AST], SGPT [ALT], sodium. 7Serum Pregnancy test done 48 hours before start of therapy 8Optional blood draw 9CT, MRI, or PET within 0 days (14 days preferre d) is acceptable for imaging assessment purposes NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 64 9 Radiologic evaluations done at weeks 8 and 16 +/-7 days. If a clinical response is seen at week 8 a confirmatory scan is to be repeated at least 4 weeks later (week 12), therefore the week 16 scan can be delayed an additional 4 weeks and repeated at week 20. After week 26 s cans are to be done every 12 week s in patients without progression through year 5 of follow-up. * Pretreatment biopsies should be performed before the first treatment with IDO inhibitor, within 14 days of that start date. **A participant will be taken off protocol treatment if >1 vaccination is delayed [  3 to 7 days] during the treatment period. ***For cycles beyond cycle 1, correlative science blood draw s will be limited to only IFN-gamma ELISpot/PBMC Storage. NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 65 11. MEASUREMENT OF EFFECT In all patients, assessments for toxicology, response, and pharmacodynamics for immunologic effect will be performed. Effects of IDO inhibitio n on systemic vaccine-induced immunity will be assessed by evaluating peripheral blood immune responses to the MELITAC 12.1 vaccine. The comparator for immune responses will be published experience with similar patients treated with the same vaccine regimen but without INCB024360 [ Slingluff, 2011; Slingluff 2009 ]. If substantial changes at sites of tumor are de tected in response to INCB024360 alone or in combination with vaccine, subsequent iterative tria ls will determine the individual contributions of INCB024360 and the vaccine. From these data, we will endeavor to associate any observed changes with the expression of IDO1 protein by IHC in tumor or tumor-infiltrating cells. The primary endpoint will be change s in the concentration and numb er of CD8+ cells infiltrating tumor before and after treatment with each patien t serving as their own control. We will use the assessment of total CD3 T cells and total CD45 lymphocytes as confirmatory assays. The histologic pattern of T-cell infiltration and changes in pattern will be concurrently assessed and chronicled. Whether to expect a small or larg e effect on the tumor microenvironment from the therapy remains unknown, thus the endpoint objectiv es are exploratory an d the trial is sized accordingly. A prior study of changes in the tumor microenvironment with systemic immune therapy (IL-2) identified significant changes in th e tumor microenvironment with a sample size of 13 patients. The sample size of 12 patients is a reasonable number for th is initial study to determine whether INCB024360 plus vaccine ha s an appreciable effect on the tumor microenvironment. Each patient’s tumor(s) will be biopsied before therapy and during therapy to assess the extent to which INCB024360 plus MELITAC 12.1 alters the tumor as evaluated by IHC and transcriptome analysis. In addition, the effect on immune responses in periph eral blood and on PBMC phenotype and character will be assessed (1) before therapy, (2) on day 21, before the first vaccine, (3) on day 42, a week after the third vaccine and coincidi ng with the day 42 biopsy, and (4) at week 16, 2 weeks after the sixth vaccine. Therapeutic response will be a ssessed by serial scans and measur es of circulating tumor cells. Overall clinical response rate and tumor progr ession will be assessed by evaluating nonbiopsied lesions if present, using standard methods (RECIST and irRC), including physical exam and CT scans performed before therapy, at weeks 8, 16, 26 and every 3 months through 1 year according to standard practice. If a clinical response is seen at week 8 a conf irmatory scan is to be repeated at least 4 weeks later (week 12), therefore obtaining the week 16 scan may be delayed an additional 4 weeks and repeated at week 20. After week 26 scans are to be done every 12 weeks in patients without progression. Both systems will be used for reporting response. Patients may be managed in accordance with irRC guid elines as published by Wolchok [Wolchok 2009 ]. The irRC criteria allow for reporting as “response” patients that respond after a period of progression. The irRC criteria accordingly do not demand immediate cessa tion of experimental therapy with the first sign of progression. In addition, the safety and to lerability of INCB024360 with MELITAC 12.1 will be assessed in this study utilizing the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (NCI CTCAE v4.0). NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 66 11.1 Antitumor Effect – Solid Tumors For the purposes of this study, patients shoul d be evaluated for re sponse according to standard practice at weeks 8, 16, 26 and every 3 months thereafter thro ugh year 1 according to standard practice . In addition to a baseline scan, confirmatory scans should also be obtained at least 4 weeks afte r the initial documentation of objective response (i.e., week 12). A 4 week delay in obtaining the week 16 s cans, (i.e., obtaining scans at week 20), would be acceptable due to the timing of obtaining confirmatory response scans. . Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Ev aluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [ Eisenhauer 2009 ]. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the s hortest diameter in the case of malignant lymph nodes are used in the RECIST criteria . Results will be reported by RECIST and irRC guidelines.